BioCentury

7:00 AM GMT, Sep 18, 2006
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Strategy

Commercial NOtions

With lead compound naproxicinod completing its first Phase III trial in osteoarthritis ahead of schedule and having decided to develop NCX 4016 to treat Type II diabetes, NicOx S.A. is now focusing on making the transition from a research company to a fully integrated specialty pharmaceuticals business with franchises in rheumatology and cardiometabolism. The company laid out its new strategy for the first time last week.

"I haven't seen any company achieve success without selling its own drugs," Chairman

Read the full 785 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.